Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 1/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.31 |
| ▸ | CDC25B | P30305 | 3/20 | 0.31 |
| ▸ | PDE2A | O00408 | 2/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13532037 | 0.93 | TNK2 (0.33) | TNK2RIPK1 | |
| SCHEMBL12393393 | 0.88 | HSPA5 (0.36) | HSPA5TNK2PTPN1CDC25BPDE2A | |
| SCHEMBL19088037 | 0.88 | HSPA5 (0.36) | HSPA5TNK2PTPN1CDC25BPDE2A | |
| SCHEMBL10082719 | 0.88 | HSPA5 (0.36) | HSPA5TNK2PTPN1CDC25BPDE2A | |
| SCHEMBL12393217 | 0.88 | HSPA5 (0.35) | HSPA5TNK2PDE2ARIPK1BCHE | |
| SCHEMBL12243182 | 0.85 | HSPA5 (0.33) | HSPA5TNK2PDE2ABCHE | |
| SCHEMBL12393231 | 0.85 | HSPA5 (0.33) | HSPA5PDE2A | |
| SCHEMBL12393368 | 0.85 | HSPA5 (0.33) | HSPA5PDE2A | |
| SCHEMBL17453586 | 0.85 | HSPA5 (0.33) | HSPA5TNK2PDE2ABCHE | |
| SCHEMBL10083635 | 0.85 | HSPA5 (0.33) | HSPA5TNK2PDE2ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46762-E1 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC (US) | 2018-03-27 | — | — | US | disclosed |
| US-8008264-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, MTAP, SLC29A1 | HSPA5 2596/4885TNK2 1494/4885PTPN1 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.